Maximizing Outcomes in Relapsed/Refractory Multiple Myeloma: Tailoring Bispecific Antibody Approaches : Episode 4
Bispecifics in R/R MM: Selecting the Best Bispecific and Optimal Sequencing Strategies
Dr Mohan asks Dr Nadeem about the selection process among bispecific antibodies, the factors influencing decision-making, and the use of talquetamab, teclistamab, or elranatamab in specific patient subgroups, followed by a discussion with Dr Mann on next therapeutic steps if a patient experiences disease progression on talquetamab.
Video Player is loading.
Video content above is prompted by the following:
- How do you approach the selection process among the various available bispecific antibodies?
- What key factors influence your decision?
- In which specific patient subgroups would you lean toward using talquetamab, teclistamab, or elranatamab?
- If this patient were to experience disease progression on talquetamab, what would be your next therapeutic approach and why?
- What considerations would guide your decision-making process?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
